Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.67 |
| ▸ | PIK3CB | P42338 | 19/20 | 0.67 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.67 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.67 |
| ▸ | SRC | P12931 | 1/20 | 0.67 |
| ▸ | DDX6 | P26196 | 1/20 | 0.67 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
| ▸ | CSK | P41240 | 1/20 | 0.67 |
| ▸ | MTOR | P42345 | 1/20 | 0.67 |
| ▸ | PLK1 | P53350 | 1/20 | 0.67 |
| ▸ | PRKDC | P78527 | 1/20 | 0.67 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.67 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.67 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | AKT1 | P31749 | 1/20 | 0.55 |
| ▸ | AKT2 | P31751 | 1/20 | 0.55 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32688222 | 0.91 | PIK3CA (0.66) | PIK3CAPIK3CBPIK3CDPIK3CGSRC | |
| SCHEMBL1808046 | 0.87 | PIK3CB (0.68) | PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL30780577 | 0.82 | PIK3CA (0.68) | PIK3CAPIK3CBPIK3CDPIK3CGSRC | |
| SCHEMBL13752211 | 0.81 | PIK3CB (0.69) | PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1 | |
| Azd-6482 SCHEMBL4353531 | 0.80 | PIK3CB (1.00) | PIK3CAPIK3CBPIK3CDPIK3CGSRC | |
| Azd-6482 SCHEMBL1812377 | 0.80 | PIK3CB (1.00) | PIK3CAPIK3CBPIK3CDPIK3CGSRC | |
| Azd-6482 SCHEMBL825695 | 0.80 | PIK3CB (1.00) | PIK3CAPIK3CBPIK3CDPIK3CGSRC | |
| Azd-6482 SCHEMBL29361545 | 0.80 | PIK3CB (1.00) | PIK3CAPIK3CBPIK3CDPIK3CGSRC | |
| SCHEMBL880820 | 0.80 | PIK3CB (0.73) | PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL21749825 | 0.79 | PIK3CB (0.67) | PIK3CAPIK3CBPIK3CDPIK3CGSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4076450-B1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS INC (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4153597-B1 | CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | PHARMACOSMOS HOLDING AS (DK) | 2025-09-10 | — | — | EP | disclosed |
| US-20250127903-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-3386968-B1 | BENZOTHIOPHENE-BASED SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR COMPOUNDS | UNIV ILLINOIS (US) | 2025-04-02 | — | — | EP | disclosed |
| EP-4483875-A2 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-4455146-A2 | MORPHIC FORMS OF GIT38 AND METHODS OF MANUFACTURE THEREOF | G1 Therapeutics, Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-3454862-B1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-3454856-B1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-118344370-A | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2024-07-16 | — | — | CN | disclosed |
| EP-4384162-A1 | COMPOSITIONS AND METHODS FOR EXTENDED RELEASE CROMAKALIM THERAPY | Qlaris Bio, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| WO-2017112823-A1 | TARGETED SELECTION OF PATIENTS FOR TREATMENT WITH SPECIFIC CORTISTATIN DERIVATIVES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017083779-A1 | AGGREGATING MICROPARTICLES FOR THERAPY | Graybug Vision, Inc. (US) | 2017-05-18 | — | — | WO | disclosed |
| WO-2016182904-A1 | TARGETED SELECTION OF PATIENTS FOR TREATMENT WITH CORTISTATIN DERIVATIVES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-17 | — | — | WO | disclosed |
| EP-3003309-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | Infinity Pharmaceuticals, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| WO-2016040858-A1 | COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2016040848-A1 | TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| EP-2914296-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | Infinity Pharmaceuticals, Inc. (US) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014194254-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014071109-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20090191177-A1 | Enantiomerically Pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-A]pyrimidin-9-yl)ethylamino]benzoic Acid, Its Use In Medical Therapy, And A Pharmaceutical Composition Comprising It - 026 | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127903-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, NEDD4 | PIK3CA 4138/4885PIK3CB 3699/4885PIK3CD 3448/4885 |
| US-20090191177-A1 | Enantiomerically Pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-A]pyrimidin-9-yl)ethylamino]benzoic Acid, Its Use In Medical Therapy, And A Pharmaceutical Composition Comprising It - 026 | ITK, PI4KA, PIK3CA | PIK3CA 3/4885PIK3CB 9/4885PIK3CD 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.